BridgeBio Pharma (BBIO) EPS (Weighted Average and Diluted) (2020 - 2026)
BridgeBio Pharma's (BBIO) quarterly EPS (Weighted Average and Diluted) came in at -$0.84 in Q1 2026, up 4.55% year-on-year from -$0.8 in Q1 2025, and up 15.15% quarter-over-quarter from -$0.99 in Q4 2025.
BridgeBio Pharma (BBIO) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
BridgeBio Pharma has disclosed EPS (Weighted Average and Diluted) across 7 years of filings, most recently posting -$0.84 for Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.84, up 4.55% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.73 (down 5.07% YoY), and the FY2025 annual result was -$3.78, down 31.25% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.84 for Q1 2026 at BridgeBio Pharma, up from -$0.99 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.07 in Q2 2022 to a low of -$1.42 in Q4 2024.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.93 (2022), against an average of -$0.86.
- Across the five-year window, EPS (Weighted Average and Diluted) soared 89.39% in 2022 and sank 1300.0% in 2023, its largest moves.
- BridgeBio Pharma's EPS (Weighted Average and Diluted) stood at -$0.92 in 2022, then fell by 4.35% to -$0.96 in 2023, then slumped by 47.92% to -$1.42 in 2024, then soared by 30.28% to -$0.99 in 2025, then grew by 15.15% to -$0.84 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.84 (Q1 2026), -$0.99 (Q4 2025), and -$0.95 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | BridgeBio Pharma | 12.90 Bn | 11.97 Bn | 184.58 Mn | -0.84 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.84 |
| Dec 31, 2025 | -0.99 |
| Sep 30, 2025 | -0.95 |
| Jun 30, 2025 | -0.95 |
| Mar 31, 2025 | -0.88 |
| Dec 31, 2024 | -1.42 |
| Sep 30, 2024 | -0.86 |
| Jun 30, 2024 | -0.39 |
| Mar 31, 2024 | -0.20 |
| Dec 31, 2023 | -0.96 |
| Sep 30, 2023 | -1.08 |
| Jun 30, 2023 | -0.98 |
| Mar 31, 2023 | -0.92 |
| Dec 31, 2022 | -0.92 |
| Sep 30, 2022 | -0.93 |
| Jun 30, 2022 | -0.07 |
| Mar 31, 2022 | -1.35 |
| Dec 31, 2021 | -1.02 |
| Sep 30, 2021 | -1.06 |
| Jun 30, 2021 | -0.66 |